MANNY ROSSMAN

S.169: I-Squared Act of 2013 and S. 744: Security, Economic Opportunity, and Immigration Modernization Act.

Issues regarding corporate tax proposala, including extension and permanence of the R&D Tax Credit; S. 2260 (EXPIRE Act); H.R. 4428, American Research and Competitiveness Act of 2014.

Issues related to the need to reform government surveillance programs, including additional substantive and procedural privacy protections and providing more transparency around national security-related orders; FISA Improvement Act of 2013 (S.1631); USA FREEDOM Act (S.1599); and USA FREEDOM Act (H.R. 3361).

Issues related to comprehensive tax reform and the tax treatment of foreign-owned U.S. corporations. Tax extender legislation, the Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act and H.R. 4438, the American Research and Competitiveness Act of 2014.

S.169: I-Squared Act of 2013 S. 744, Security, Economic Opportunity, and Immigration Modernization Act

Discussions regarding need to reform government surveillance programs, including additional substantive and procedural privacy protections and providing more transparency around national security-related orders; FISA Improvement Act of 2013 (S.1631); USA FREEDOM Act (S.1599); and USA FREEDOM Act (H.R. 3361).

Issues regarding corporate tax proposala, including extension and permanence of the R&D Tax Credit; S. 2260 (EXPIRE Act); H.R. 4428, American Research and Competitiveness Act of 2014.

Federal estate and gift tax reform.

Issues related to comprehensive tax reform and the tax treatment of foreign-owned U.S. corporations. Tax extender legislation, the Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act, including the R & D tax credit.

S.169: I-Squared Act of 2013 S. 744, Security, Economic Opportunity, and Immigration Modernization Act

Expiring Provisions Improvement Reform and Efficiency (EXPIRE)Act (tax extenders), including the R&D tax credit. (no bill number)

Federal estate and gift tax reform.

Issues related to comprehensive tax reform and the tax treatment of foreign-owned U.S. corporations. Tax extender legislation, the Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act, including the R & D tax credit.

S.169: I-Squared Act of 2013 S. 744, Security, Economic Opportunity, and Immigration Modernization Act

S.268, CUT Loopholes Act

Federal estate and gift tax reform.

FY14 appropriations bills, including issues related to FDA funding and drug approval/review oversight process; and sequestration process. Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R&D tax credit. Corporate tax reform issues. International trade issues and patent protection abroad.

S.268, CUT Loopholes Act

S.169: I-Squared Act of 2013 S. 744, Security, Economic Opportunity, and Immigration Modernization Act

Federal estate and gift tax reform.

FY14 appropriations bills, including issues related to FDA funding and drug approval/review oversight process; and sequestration process. Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R&D tax credit. Corporate tax reform issues. International trade issues and patent protection abroad.

Federal estate and gift tax reform.

FY14 appropriations bills, including issues related to FDA funding and drug approval/review oversight process. Monitor sequestration process. Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R&D tax credit. Corporate tax reform issues. International trade issues and patent protection abroad.

S.169: I-Squared Act of 2013 S. 744, Security, Economic Opportunity, and Immigration Modernization Act

S.268, CUT Loopholes Act

Federal estate and gift tax reform.

FY13 appropriations bills, including issues related to FDA funding and drug approval/review oversight process. FY13 CR and sequestration process. Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R&D tax credit. Corporate tax reform issues. International trade issues and patent protection abroad.

S.268, CUT Loopholes Act

S.169: I-Squared Act of 2013

Issues related to Estate and Gift Tax reform

S.1857, Fairness for High-Skilled Immigrants Act.

Online privacy issues including implementation of Children's Online Privacy Protection Act (COPPA).

Cyber security legislation (S. 2105, Cyber Security Act of 2012).

Federal estate and gift tax reform.

FY13 appropriations bills, including issues related to FDA funding and drug approval/review oversight process. Monitored legislation related to altering sequestration targets. Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R & D tax credit. S.3521, Family and Business Tax Cut Certainty Act of 2012 (tax "extenders"). Corporate tax reform issues. Monitored fiscal clif legislation - American Taxpayer Releif Act (H.R.8).

Federal estate and gift tax reform.

Cyber security legislation (S. 2105, Cyber Security Act of 2012).

S.1857, Fairness for High-Skilled Immigrants Act.

Online privacy issues including implementation of Children's Online Privacy Protection Act (COPPA).

FY13 appropriations bills, including issues related to FDA funding and drug approval/review oversight process. Legislation related to altering sequestration targets. Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R & D tax credit. S.3521, Family and Business Tax Cut Certainty Act of 2012 (tax "extenders"). Corporate tax reform issues.

Implementation of healthcare reform law. FDA drug approval and appeal oversight process. Issues related to patient and physician choice in medical treatments. PDUFA reauthorization.

Issues related to technology and internet policy, including personal privacy, protecting children, advancing online security, and tax policy issues.

Issues related to technology and internet policy, including personal privacy, protecting children, advancing online security, and tax policy issues.

Issues related to technology and internet policy, including personal privacy, protecting children, advancing online security, and tax policy issues.

Revision of the Flexible Spending Account use-it-or-lose-it rule.

Federal estate and gift tax reform.

Implementation of FATCA

Implementation of FATCA

Implementation of healthcare reform law. FDA drug approval and appeal oversight process. Issues related to patient and physician choice in medical treatments. PDUFA reauthorization.

FY13 appropriations bills, including issues related to FDA funding and drug approval/review oversight process. Legislation related to altering sequestration targets. Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R & D tax credit.

Federal estate and gift tax reform.

Monitor FY13 appropriations process: FDA funding issues and drug approval/review oversight process. Monitor the potential outcomes for negotiations on altering sequestration targets via legislation. Monitor plans for issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders (R & D tax credit).

Implementation of healthcare reform law. FDA Drug Approval and appeal oversight process. Issues related to patient and physician choice in medical treatments.

Issues around the implementation of new health care exchange rules

Issues around the implementation of new health care exchange rules

Implementation of healthcare reform law. FDA Drug Approval and appeal oversight process. Issues related to patient and physician choice in medical treatments. PATIENTS Act (S.660)

FY12 appropriations process, including H.R. 2112 and various Continuing Resolutions: FDA funding issues and drug approval/review oversight process. Monitor tax and healthcare policy changes in Super Committee negotiations.

FY12 appropriations process, including H.R. 2112 and various Continuing Resolutions: FDA funding issues and drug approval/review oversight process.

Implementation of healthcare reform law. FDA Drug Approval and appeal oversight process. Support for legislation preserving patient and physician choice in medical treatments. PATIENTS Act (S.660)

Implementation of healthcare reform law. FDA Drug Approval and appeal oversight process. Support for legislation preserving patient and physician choice in medical treatments. PATIENTS Act (S.660)

FY11 appropriations process - including H.R.1 and various Continuing Resolutions: FDA funding issues and drug approval/review oversight process.

Implementation of healthcare reform law. FDA Drug Approval and appeal oversight process.

FY11 appropriations process - including H.R.1 and various Continuing Resolutions: FDA funding issues and drug approval/review oversight process.

Issues related to the use of Avastin.

FY12 appropriations process, including H.R. 2112 and various Continuing Resolutions: FDA funding issues and drug approval/review oversight process. Monitor tax and healthcare policy changes in Super Committee negotiations.

Implementation of healthcare reform law. FDA Drug Approval and appeal oversight process. Issues related to patient and physician choice in medical treatments. PATIENTS Act (S.660)

H.R. 1834, Freedom to Invest Act of 2011 (repatriation "holiday" legislation). Tax issues relating to comprehensive corporate tax reform, including deferral and territorial taxation.

Federal estate and gift tax reform.

CMS-1503-P Medicare Programs; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2011 Proposed Rule; CMS-3206-P End-Stage Renal Disease Quality Incentive Program Proposed Rule; The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); End-Stage Renal Disease Prospective Payment System Proposed Rule; Budget Control Act (P.L. 112-25)

CMS-1503-P Medicare Programs; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2011 Proposed Rule; CMS-3206-P End-Stage Renal Disease Quality Incentive Program Proposed Rule; The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); End-Stage Renal Disease Prospective Payment System Proposed Rule; Budget Control Act (P.L.112-25)

Implementation of FATCA.

Implementation of FATCA.

H.R. 1834, Freedom to Invest Act of 2011 (repatriation "holiday" legislation). Tax issues relating to comprehensive corporate tax reform, including deferral and territorial taxation.

Federal estate and gift tax reform.

Issues related to Estate and Gift Tax reform

CMS-1418-F ESRD Prospective Payment System Final Rule; CMS-1503-P Medicare Programs; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2011 Proposed Rule; CMS-3206-P End-Stage Renal Disease Quality Incentive Program Proposed Rule; The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); End-Stage Renal Disease Prospective Payment System Proposed Rule; Budget Control Act (P.L.112-25)

CMS-1418-F ESRD Prospective Payment System Final Rule; CMS-1503-P Medicare Programs; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2011 Proposed Rule; CMS-3206-P End-Stage Renal Disease Quality Incentive Program Proposed Rule; The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); End-Stage Renal Disease Prospective Payment System Proposed Rule; Budget Control Act (P.L. 112-25)

FY12 appropriations process, including H.R. 2112 and various Continuing Resolutions: FDA funding issues and drug approval/review oversight process.

Implementation of healthcare reform law. FDA Drug Approval and appeal oversight process. Support for legislation preserving patient and physician choice in medical treatments. PATIENTS Act (S.660)

Implementation of FATCA.

Implementation of FATCA.

Regulation of the over-the-counter derivatives market. H.R. 4173, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.

H.R. 1834, Freedom to Invest Act of 2011 (repatriation "holiday" legislation). Tax issues relating to comprehensive corporate tax reform, including deferral and territorial taxation.

Federal estate and gift tax reform.

Issues related to Estate and Gift Tax reform

CMS-1418-F ESRD Prospective Payment System Final Rule; CMS-1503-P Medicare Programs; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2011 Proposed Rule; CMS-3206-P End-Stage Renal Disease Quality Incentive Program Proposed Rule; The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); End-Stage Renal Disease Prospective Payment System

CMS-1418-F ESRD Prospective Payment System Final Rule; CMS-1503-P Medicare Programs; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2011 Proposed Rule; CMS-3206-P End-Stage Renal Disease Quality Incentive Program Proposed Rule; The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); End-Stage Renal Disease Prospective Payment System; Changes to the End-Stage Renal Disease Prospective Payment System Transition Budget-Neutrality Adjustment Interim Final Rule

Implementation of FATCA.

Implementation of FATCA.

Issues related to H.R.1834, Freedom to Invest Act of 2011. Tax issues relating to comprehensive corporate tax reform, including deferral and territorial taxation.

Regulation of the over-the-counter derivatives market. H.R. 4173, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.

FY11 appropriations process - including H.R.1 and various Continuing Resolutions: FDA funding issues and drug approval/review oversight process.

Implementation of healthcare reform law. FDA Drug Approval and appeal oversight process. Support for legislation preserving patient and physician choice in medical treatments. PATIENTS Act (S.660)

FY11 appropriations process - including H.R.1 and various Continuing Resolutions: FDA funding issues and drug approval/review oversight process.

Implementation of healthcare reform law. FDA Drug Approval and appeal oversight process.

Federal estate and gift tax reform.

Estate and Gift Tax Reform

Regulation of the over-the-counter derivatives market. H.R. 4173, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.

Issues related to the use of Avastin.

Implementation of FATCA.

Implementation of FATCA.

H.R. 4853: Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act of 2010

Regulation of the over-the-counter derivatives market. H.R. 4173, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.

Legislation and regulation concerning safety of imported foods, food processing safety, the Supplemental Nutrition Assistance Program, Dietary Guidelines for Americans, and food labeling. H.R. 2749, FDA Globalization Act of 2009, and S. 510 Food Safety Modernization Act. Anti-obesity legislation, child nutrition legislation, labeling and advertising legislation: S 3307, Health, Hunger-Free Kids Act of 2010, H.R. 5504, Improving Nutrition for America's Children Act. West Africa cocoa supply. FY 2011 Agriculture appropriations: USDA cocoa research, rice farming, peanut research.

Estate and Gift Tax Reform: H.R. 4853.

Issues related to taxation of dividends and capital gains.

Estate and Gift Tax Reform.

Issues related to the taxation of dividends.

H.R. 4213, The American Jobs and Closing Tax Loopholes Act of 2010, H.R. 4173, The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.